afamelanotide in fair-skinned Parkinsons patients
Filed with ASX · · 3 pages · English
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL initiates on market share buy-back program
- New case of SCENESSE efficacy in vitiligo presented at AAD
- SCENESSE provides photoprotection in variegate porphyria
- CUV Appendix 4D Half Year Report
- Appendix 4E and Annual Report to Shareholders 2023
Later from Clinuvel Pharmaceuticals
- CLINUVEL extends Managing Director Employment Agreement
- Afamelanotide Assists DNA Repair Response Following UVR
- Vitiligo and Operational Update
- Appendix 4E and Annual Report to Shareholders 2024
- CLINUVEL delivers increases in annual revenue, profit
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals